150 related articles for article (PubMed ID: 11463061)
1. Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Milionis HJ; Bairaktari ET; Liberopoulos EN; Elisaf MS
Am J Cardiol; 2001 Jul; 88(2):203. PubMed ID: 11463061
[No Abstract] [Full Text] [Related]
2. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
3. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Lemieux I; Salomon H; Després JP
Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Henry K; Melroe H; Huebesch J; Hermundson J; Simpson J
Lancet; 1998 Sep; 352(9133):1031-2. PubMed ID: 9759748
[No Abstract] [Full Text] [Related]
5. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Otto C; Otto B; Frost RJ; Vogeser M; Pfeiffer AF; Spranger J; Parhofer KG
Acta Diabetol; 2007 Jun; 44(2):65-8. PubMed ID: 17530469
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
[TBL] [Abstract][Full Text] [Related]
7. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
Després JP; Lemieux I; Salomon H; Delaval D
J Intern Med; 2002 Jun; 251(6):490-9. PubMed ID: 12028504
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Bairaktari ET; Tzallas CS; Tsimihodimos VK; Liberopoulos EN; Miltiadous GA; Elisaf MS
J Cardiovasc Risk; 1999 Apr; 6(2):113-6. PubMed ID: 10353071
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Ooi TC; Heinonen T; Alaupovic P; Davignon J; Leiter L; Lupien PJ; Sniderman AD; Tan MH; Tremblay G; Sorisky A; Shurzinske L; Black DM
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1793-9. PubMed ID: 9327779
[TBL] [Abstract][Full Text] [Related]
11. Status report of lipid-lowering trials in diabetes.
Betteridge DJ; Colhoun H; Armitage J
Curr Opin Lipidol; 2000 Dec; 11(6):621-6. PubMed ID: 11086336
[TBL] [Abstract][Full Text] [Related]
12. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
13. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
Kastelein JJ; Isaacsohn JL; Ose L; Hunninghake DB; Frohlich J; Davidson MH; Habib R; Dujovne CA; Crouse JR; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB
Am J Cardiol; 2000 Jul; 86(2):221-3. PubMed ID: 10913488
[No Abstract] [Full Text] [Related]
14. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
[TBL] [Abstract][Full Text] [Related]
15. Statin therapy works for patients who have type 2 diabetes.
Korber KE
JAAPA; 2008 Oct; 21(10):58, 60. PubMed ID: 19024640
[No Abstract] [Full Text] [Related]
16. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
Giral P; Bruckert E; Jacob N; Chapman MJ; Foglietti MJ; Turpin G
Atherosclerosis; 2001 Feb; 154(2):421-7. PubMed ID: 11166775
[TBL] [Abstract][Full Text] [Related]
17. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
[TBL] [Abstract][Full Text] [Related]
18. Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Mohrschladt MF; Weverling-Rijnsburger AW; de Man FH; Stoeken DJ; Sturk A; Smelt AH; Westendorp RG
Atherosclerosis; 2000 Feb; 148(2):413-9. PubMed ID: 10657578
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
[TBL] [Abstract][Full Text] [Related]
20. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Malik J; Melenovsky V; Wichterle D; Haas T; Simek J; Ceska R; Hradec J
Cardiovasc Res; 2001 Nov; 52(2):290-8. PubMed ID: 11684077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
